#VisualAbstract: Everolimus plus leuprorelin and letrozole improves progression-free survival in HR⁺, HER2⁻ metastatic breast cancer patients with visceral metastases
#VisualAbstract: Low-dose capecitabine after standard adjuvant therapy improves disease-free survival in patients with early triple-negative breast cancer
#VisualAbstract: Low mammographic breast density may be associated with an increased risk of developing severe lymphedema
#VisualAbstract: Neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen shows high cost-effectiveness for ERBB2-positive breast cancer
#VisualAbstract: Pembrolizumab plus chemotherapy improves survival in patients with metastatic triple-negative breast cancer
Regulatory Alerts, Cancer, Oncology, Breast cancer, Gastrointestinal cancer, Head and neck cancer, Oncology Room
5-fluorouracil (intravenous), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at increased risk of severe and fatal toxicity
Patients with complete or partial dihydropyrimidine dehydrogenase (DPD) deficiency are at increased risk of severe and fatal toxicity during treatment with these medicines.